JP2019529500A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019529500A5 JP2019529500A5 JP2019517777A JP2019517777A JP2019529500A5 JP 2019529500 A5 JP2019529500 A5 JP 2019529500A5 JP 2019517777 A JP2019517777 A JP 2019517777A JP 2019517777 A JP2019517777 A JP 2019517777A JP 2019529500 A5 JP2019529500 A5 JP 2019529500A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- group
- alkyl
- compound according
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 *c1ccccc1C1(CC1)Nc1c(C=NC(C2C3)C2=C([C@@]2O)OC(C4)(C4OCPO)[C@@]2O)c3nc(Cl)n1 Chemical compound *c1ccccc1C1(CC1)Nc1c(C=NC(C2C3)C2=C([C@@]2O)OC(C4)(C4OCPO)[C@@]2O)c3nc(Cl)n1 0.000 description 2
Images
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022158467A JP2022173493A (ja) | 2016-10-03 | 2022-09-30 | アデノシン５’－ヌクレオチダーゼの阻害剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662403598P | 2016-10-03 | 2016-10-03 | |
| US62/403,598 | 2016-10-03 | ||
| PCT/US2017/054694 WO2018067424A1 (en) | 2016-10-03 | 2017-10-02 | Inhibitors of adenosine 5'-nucleotidase |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022158467A Division JP2022173493A (ja) | 2016-10-03 | 2022-09-30 | アデノシン５’－ヌクレオチダーゼの阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019529500A JP2019529500A (ja) | 2019-10-17 |
| JP2019529500A5 true JP2019529500A5 (cg-RX-API-DMAC10.html) | 2021-04-15 |
| JP7184761B2 JP7184761B2 (ja) | 2022-12-06 |
Family
ID=61831914
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019517777A Active JP7184761B2 (ja) | 2016-10-03 | 2017-10-02 | アデノシン５’－ヌクレオチダーゼの阻害剤 |
| JP2022158467A Withdrawn JP2022173493A (ja) | 2016-10-03 | 2022-09-30 | アデノシン５’－ヌクレオチダーゼの阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022158467A Withdrawn JP2022173493A (ja) | 2016-10-03 | 2022-09-30 | アデノシン５’－ヌクレオチダーゼの阻害剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US11058704B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3518934A4 (cg-RX-API-DMAC10.html) |
| JP (2) | JP7184761B2 (cg-RX-API-DMAC10.html) |
| CN (1) | CN110049767B (cg-RX-API-DMAC10.html) |
| TW (1) | TWI781960B (cg-RX-API-DMAC10.html) |
| WO (1) | WO2018067424A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018067424A1 (en) | 2016-10-03 | 2018-04-12 | Arcus Biosciences, Inc. | Inhibitors of adenosine 5'-nucleotidase |
| US20200115404A1 (en) | 2017-03-31 | 2020-04-16 | Peloton Therapeutics, Inc. | Cd73 inhibitors and uses thereof |
| US11129841B2 (en) | 2017-05-10 | 2021-09-28 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
| WO2019090111A1 (en) | 2017-11-03 | 2019-05-09 | Oric Pharmaceuticals, Inc. | Cd73 inhibitors |
| WO2019129059A1 (zh) * | 2017-12-29 | 2019-07-04 | 上海和誉生物医药科技有限公司 | 一种具有cd73抑制活性的膦酸衍生物、其制备方法和应用 |
| JP7417530B2 (ja) * | 2018-03-09 | 2024-01-18 | アーカス バイオサイエンシズ インコーポレイティド | 優先投与される免疫増強薬 |
| KR20210018255A (ko) | 2018-04-30 | 2021-02-17 | 오릭 파마슈티칼스, 인크. | Cd73 억제제 |
| EP3810109B1 (en) | 2018-05-31 | 2024-08-07 | Peloton Therapeutics, Inc. | Compounds and compositions for inhibiting cd73 |
| CN112638389A (zh) * | 2018-08-28 | 2021-04-09 | 江苏恒瑞医药股份有限公司 | Cd73抑制剂及其治疗用途 |
| JOP20210164A1 (ar) | 2019-01-11 | 2023-01-30 | Omeros Corp | طرق وتركيبات علاج السرطان |
| WO2020151707A1 (zh) * | 2019-01-22 | 2020-07-30 | 江苏恒瑞医药股份有限公司 | 一种新型的小分子cd73抑制剂、其制备方法及其在医药上的应用 |
| EP3937964A4 (en) | 2019-03-12 | 2022-11-16 | Arcus Biosciences, Inc. | TREATMENT OF ONCOGENE-DRIVEN CANCERS |
| US20220160747A1 (en) * | 2019-03-20 | 2022-05-26 | Korea Research Institute Of Chemical Technology | Pharmaceutical composition comprising novel azolopyrimidine heterocyclic compound as active ingredient |
| WO2020205527A1 (en) | 2019-03-29 | 2020-10-08 | Arcus Biosciences, Inc. | Treatment of cancer utilizing an identified adenosine fingerprint |
| WO2020210970A1 (en) * | 2019-04-16 | 2020-10-22 | Bioardis Llc | Imidazotriazine derivatives as cd73 inhibitors |
| TWI821559B (zh) * | 2019-04-28 | 2023-11-11 | 大陸商上海和譽生物醫藥科技有限公司 | 一種cd73抑制劑，其製備方法和應用 |
| CN114502174A (zh) * | 2019-06-14 | 2022-05-13 | 南方研究院 | 2,4,7取代的-7-脱氮-2′-脱氧-2′-氟阿拉伯糖基核苷和核苷酸前药及其用途 |
| JP7557522B2 (ja) * | 2019-07-16 | 2024-09-27 | オリック ファーマシューティカルズ，インク． | Ｃｄ７３阻害剤 |
| WO2021040356A1 (en) * | 2019-08-23 | 2021-03-04 | Kainos Medicine, Inc. | C-nucleosides, c-nucleotides and their analogs, equivalents and prodrugs thereof for ectonucleotidase inhibition |
| TWI830962B (zh) * | 2019-10-30 | 2024-02-01 | 美商歐瑞克製藥公司 | Cd73抑制劑 |
| JP7474861B2 (ja) | 2020-03-19 | 2024-04-25 | アーカス バイオサイエンシーズ，インコーポレーテッド | Ｈｉｆ－２アルファの阻害剤としてのテトラリン化合物及びテトラヒドロキノリン化合物 |
| JP7776448B2 (ja) | 2020-06-02 | 2025-11-26 | アーカス バイオサイエンシズ インコーポレイティド | Ｔｉｇｉｔに対する抗体 |
| JP2024521712A (ja) | 2021-05-21 | 2024-06-04 | アーカス バイオサイエンシーズ，インコーポレーテッド | Ａｘｌ阻害化合物 |
| WO2022246177A1 (en) | 2021-05-21 | 2022-11-24 | Arcus Biosciences, Inc. | Axl compounds |
| IL312348A (en) | 2021-10-29 | 2024-06-01 | Arcus Biosciences Inc | HIF-2ALPHA inhibitors and methods of using it |
| CA3256033A1 (en) | 2022-04-13 | 2023-10-19 | Arcus Biosciences, Inc. | POLYTHERAPY FOR THE TREATMENT OF CANCERS EXPRESSING TOO MUCH-2 |
| KR20250006959A (ko) | 2022-05-02 | 2025-01-13 | 아르커스 바이오사이언시즈 인코포레이티드 | 항-tigit 항체 및 이의 용도 |
| CN117321066A (zh) | 2022-07-12 | 2023-12-29 | 南京工业大学 | 一种基于虫草素经衍生化具有抗肿瘤效应的化合物 |
| CN116768949A (zh) * | 2022-07-12 | 2023-09-19 | 南京工业大学 | 一种基于3’-脱氧腺苷经化学修饰改性的具有抗癌效应的化合物 |
| EP4554680A1 (en) | 2022-07-15 | 2025-05-21 | Arcus Biosciences, Inc. | Inhibitors of hpk1 and methods of use thereof |
| US20260028336A1 (en) | 2022-07-20 | 2026-01-29 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| AU2023341373A1 (en) | 2022-09-14 | 2025-03-06 | Arcus Biosciences, Inc. | Dispersions of etrumadenant |
| WO2024081385A1 (en) | 2022-10-14 | 2024-04-18 | Arcus Biosciences, Inc. | Hpk1 inhibitors and methods of use thereof |
| WO2024226872A2 (en) * | 2023-04-26 | 2024-10-31 | Lakewood Amedex, Inc. | Substituted bicyclic heterocycle compounds, compositions, and uses thereof |
| US20240425497A1 (en) | 2023-05-05 | 2024-12-26 | Arcus Biosciences, Inc. | Cbl-b Inhibitors and Methods of Use Thereof |
| WO2024243502A1 (en) | 2023-05-25 | 2024-11-28 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| WO2025054339A1 (en) | 2023-09-08 | 2025-03-13 | Arcus Biosciences, Inc. | Triazolopyridine compounds as inhibitors of kit |
| WO2025072330A1 (en) | 2023-09-26 | 2025-04-03 | Arcus Biosciences, Inc. | Kit inhibitor compounds and methods of use thereof |
| TW202517260A (zh) | 2023-10-06 | 2025-05-01 | 美商阿克思生物科學有限公司 | Ｃｂｌ—ｂ抑制劑及其使用方法 |
| US12384773B2 (en) | 2023-11-02 | 2025-08-12 | Arcus Biosciences, Inc. | Thiazole compounds and methods of use thereof |
| WO2025113498A1 (zh) * | 2023-12-01 | 2025-06-05 | 无锡和誉生物医药科技有限公司 | 一种cd73抑制剂碱式盐及其制备方法和应用 |
| CN117562915A (zh) * | 2023-12-05 | 2024-02-20 | 中国药科大学 | 一种腺苷衍生物在制备预防、缓解或治疗纤维化疾病的药物中的应用 |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025193759A1 (en) | 2024-03-12 | 2025-09-18 | Gilead Sciences, Inc. | Solid forms of an azolopyrimidine compound |
| WO2026006759A1 (en) | 2024-06-28 | 2026-01-02 | Arcus Biosciences, Inc. | Pharmaceutical compositions, dosage forms, and methods of making and using same |
| CN119552122B (zh) * | 2025-01-27 | 2025-05-09 | 北京悦康科创医药科技股份有限公司 | 5'-磷酸酯修饰核苷及其制备方法与应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0468119A1 (en) * | 1990-07-24 | 1992-01-29 | Merrell Dow Pharmaceuticals Inc. | Novel carbocyclic analogs of certain nucleosides |
| US6617439B1 (en) * | 2000-06-09 | 2003-09-09 | Bar-Ilan University | C8-substituted purine nucleotide analogs |
| WO2004096233A2 (en) * | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Nucleoside phosphonate conjugates |
| BRPI0518984A2 (pt) * | 2004-12-10 | 2008-12-16 | Univ Emory | anÁlogos de nucleosÍdeo de ciclobutil substituÍdos em 2' e 3' para tratamento de infecÇÕes virais e proliferaÇço celular anormal |
| WO2006130217A2 (en) * | 2005-04-01 | 2006-12-07 | The Regents Of The University Of California | Substituted phosphate esters of nucleoside phosphonates |
| EP2021350B1 (en) * | 2006-03-21 | 2016-12-21 | Rheinische Friedrich-Wilhelms-Universität Bonn | Phosphorylated a2a receptor agonists |
| CN101528260A (zh) * | 2006-10-26 | 2009-09-09 | 协和发酵麒麟株式会社 | 肠易激综合症治疗剂 |
| WO2008121261A2 (en) * | 2007-03-28 | 2008-10-09 | Vioquest Pharmaceuticals, Inc. | Prodrugs of triciribin suitable for treatment of tumors and cancer |
| HK1203513A1 (en) | 2012-03-21 | 2015-10-30 | 艾丽奥斯生物制药有限公司 | Methods of preparing substituted nucleotide analogs |
| US9090697B2 (en) | 2013-03-15 | 2015-07-28 | Bayer Healthcare Llc | Methods for treating bleeding disorders |
| JP6657182B2 (ja) * | 2014-04-25 | 2020-03-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌治療用のｃｄ７３阻害剤としてのプリン誘導体 |
| WO2018067424A1 (en) | 2016-10-03 | 2018-04-12 | Arcus Biosciences, Inc. | Inhibitors of adenosine 5'-nucleotidase |
| US20200115404A1 (en) | 2017-03-31 | 2020-04-16 | Peloton Therapeutics, Inc. | Cd73 inhibitors and uses thereof |
-
2017
- 2017-10-02 WO PCT/US2017/054694 patent/WO2018067424A1/en not_active Ceased
- 2017-10-02 EP EP17858945.3A patent/EP3518934A4/en active Pending
- 2017-10-02 CN CN201780061650.9A patent/CN110049767B/zh active Active
- 2017-10-02 JP JP2019517777A patent/JP7184761B2/ja active Active
- 2017-10-02 US US16/338,975 patent/US11058704B2/en active Active
- 2017-10-03 TW TW106134280A patent/TWI781960B/zh active
-
2022
- 2022-09-30 JP JP2022158467A patent/JP2022173493A/ja not_active Withdrawn
-
2024
- 2024-04-08 US US18/629,820 patent/US12168023B2/en active Active
- 2024-10-30 US US18/931,852 patent/US20250319113A1/en active Pending